Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
Omalizumab in the treatment of Morbihan syndrome in an adolescent girl - case report and literature review
We present the case of an adolescent girl with MS nonresponding to 19 months of isotretinoin treatment with add-on antihistamines. Therapy with monthly administration of omalizumab (anti-IgE) for 6 months was an effective therapeutic option, improving the quality of life. Our case is the second description of omalizumab use in Morbihan syndrome, the first in an adolescent.PMID:38459887 | DOI:10.15586/aei.v52i2.978 (Source: Allergologia et Immunopathologia)
Source: Allergologia et Immunopathologia - March 9, 2024 Category: Allergy & Immunology Authors: Zofia Mazurek-Durlak Katarzyna Mularczyk Przemko Kwinta Grzegorz Lis Ewa Cichocka-Jarosz Source Type: research
